具有乳头状核特征的非浸润性滤泡性甲状腺肿瘤占携带RAS突变的「癌」的一半以上
研究在199例甲状腺癌分子检测数据库中识别出27例RAS突变肿瘤,其中16例(80%)原分类为FVPTC的肿瘤现应归为NIFTP;NIFTP占所有RAS突变「癌」的59%,占先前FNA诊断为不确定的RAS突变「癌」的63%。作者认为,当临床和超声数据支持低风险表型时,对于FNA不确定且RAS突变的结节,可考虑将腺叶切除术作为初始手术方式。
要点
- RAS突变甲状腺肿瘤中NIFTP占59%,在FNA不确定者中占63%。
- 20例FVPTC中16例(80%)现应归为NIFTP。
- 作者建议低风险表型下FNA不确定且RAS突变结节可考虑腺叶切除术。
核心结论
- NIFTP占本队列RAS突变「癌」的一半以上。
- 作者认为,当临床和超声数据支持低风险表型时,对于FNA不确定且RAS突变的结节,可考虑将腺叶切除术作为初始手术方式。
研究设计与样本
- 在2013年7月至2015年7月期间经Profile:Oncopanel分子检测的199例甲状腺癌数据库中,检索已知激活RAS突变的病例。
- 对FVPTC病例重新审阅以识别现应归类为NIFTP的肿瘤,并记录先前FNA诊断。
- 不确定FNA结果定义为意义未明的异型性/滤泡性病变、滤泡性肿瘤可疑或恶性肿瘤可疑。
主要发现
- 共识别27例RAS突变甲状腺肿瘤:15例(56%)为NRAS突变,9例(33%)为HRAS突变,3例(11%)为KRAS突变。
- 24例(89%)有先前FNA,其中19例(79%)FNA诊断为不确定。
- 手术切除标本显示FVPTC 20例(74%)、经典型PTC 2例(7%)、PTC实体变异型1例(4%)、滤泡性甲状腺癌4例(15%)。
- 20例FVPTC中16例(80%)现应归为NIFTP。
- NIFTP占所有RAS突变「癌」的59%,占先前FNA不确定的RAS突变「癌」的63%。
临床怎么用
- 作者认为,当临床和超声数据支持低风险表型时,对于FNA不确定且RAS突变的结节,可考虑将腺叶切除术作为初始手术方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing of thyroid nodules is increasingly being utilized to guide clinical management decisions. RAS mutations are the most frequent mutations detected in the context of an indeterminate fine-needle aspiration (FNA) diagnosis. The term "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) was recently introduced to promote conservative management of tumors previously classified as noninvasive follicular variant of papillary thyroid carcinoma (FVPTC). This change in terminology was based on the indolent clinical behavior of these tumors and their molecular profile, which includes frequent RAS mutations. The aim of this study was to determine the percentage of RAS-mutant "carcinomas" that would now be classified as NIFTPs. METHODS: A search was performed for cases with known activating RAS mutations in a database of 199 thyroid carcinomas that underwent molecular characterization as part of Profile:Oncopanel between July 2013 and July 2015. Cases of FVPTC were re-reviewed to identify tumors that now would be categorized as NIFTP. Preceding FNA diagnoses were recorded, and cases with an indeterminate FNA result (defined as a diagnosis of atypia/follicular lesion of undetermined significance, suspicious for follicular neoplasm, or suspicious for malignancy) were identified. RESULTS: A total of 27 RAS-mutant thyroid tumors were identified. Fifteen (56%) cases had an NRAS mutation, nine (33%) had an HRAS mutation, and three (11%) had a KRAS mutation. Twenty-four (89%) cases had a preceding FNA, 19 (79%) of which had an indeterminate FNA diagnosis. The surgical resection specimen demonstrated FVPTC in 20 (74%) cases, classical type PTC in two (7%), solid variant of PTC in one (4%), and follicular thyroid carcinoma in four (15%). Of the 20 FVPTCs, 16 (80%) would now be classified as NIFTP. NIFTPs accounted for 59% of RAS-mutant carcinomas overall and 63% of RAS-mutant carcinomas with a prior indeterminate FNA diagnosis. CONCLUSION: NIFTPs accounted for more than half of RAS-mutant "carcinomas" in this cohort. In cases where clinical and sonographic data support a low-risk phenotype, these results suggest that a lobectomy should be considered as the initial surgical approach for a nodule with an indeterminate FNA diagnosis and a RAS mutation.
引用
- Paulson VA, Shivdasani P, Angell TE, et al. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations. Thyroid. 2017. PMID: 28114855. doi:10.1089/thy.2016.0583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。